Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.25B |
| 2 |
CSX Corp
CSX
|
+$1.25B |
| 3 |
Verizon
VZ
|
+$935M |
| 4 |
Micron Technology
MU
|
+$925M |
| 5 |
Harley-Davidson
HOG
|
+$799M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Union Pacific
UNP
|
+$1.51B |
| 2 |
Philip Morris
PM
|
+$1.36B |
| 3 |
American International
AIG
|
+$1.25B |
| 4 |
McKesson
MCK
|
+$1.11B |
| 5 |
Caterpillar
CAT
|
+$931M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.27% |
| 2 | Technology | 16.26% |
| 3 | Consumer Discretionary | 11.9% |
| 4 | Financials | 11.32% |
| 5 | Communication Services | 10.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Booking.com
BKNG
$160B
| $3.04B | 0.95% |
40,566,700
+2,704,675
| +7% | +$198M |
|
27
Thermo Fisher Scientific
TMO
$224B
| $3.02B | 0.95% |
17,304,897
+3,973,136
| +30% | +$667M |
|
28
JPMorgan Chase
JPM
$962B
| $2.9B | 0.91% |
31,714,763
+765,082
| +2% | +$66M |
|
29
Canadian Natural Resources
CNQ
$98.2B
| $2.82B | 0.88% |
199,385,250
-6,051,653
| -3% | -$91.1M |
|
30
Medtronic
MDT
$116B
| $2.79B | 0.87% |
31,458,396
-2,187,417
| -7% | -$184M |
|
31
ExxonMobil
XOM
$657B
| $2.55B | 0.8% |
31,570,269
+2,058,060
| +7% | +$168M |
|
32
Teva Pharmaceuticals
TEVA
$42.6B
| $2.54B | 0.79% |
76,325,059
+9,260,426
| +14% | +$287M |
|
33
Wells Fargo
WFC
$265B
| $2.51B | 0.79% |
45,327,803
+7,445,414
| +20% | +$399M |
|
34
GE Aerospace
GE
$380B
| $2.46B | 0.77% |
19,031,122
+2,987,265
| +19% | +$409M |
|
35
Boeing
BA
$184B
| $2.46B | 0.77% |
12,439,703
-3,703,138
| -23% | -$689M |
|
|
TFCFA
36
DELISTED
Twenty-First Century Fox, Inc. Class A
TFCFA
| $2.43B | 0.76% |
85,581,646
+14,398,422
| +20% | +$414M |
|
37
Lockheed Martin
LMT
$138B
| $2.38B | 0.75% |
8,582,761
-398,800
| -4% | -$110M |
|
38
Abbott
ABT
$190B
| $2.31B | 0.72% |
47,589,663
+14,918,038
| +46% | +$675M |
|
39
Illumina
ILMN
$29.1B
| $2.26B | 0.71% |
13,376,025
-970,722
| -7% | -$168M |
|
40
Las Vegas Sands
LVS
$29.6B
| $2.23B | 0.7% |
34,911,446
-2,681,809
| -7% | -$161M |
|
41
Skyworks Solutions
SWKS
$10.2B
| $2.21B | 0.69% |
23,040,672
+12,650
| +0.1% | +$1.3M |
|
42
Coca-Cola
KO
$372B
| $2.17B | 0.68% |
48,442,413
-2,981,078
| -6% | -$132M |
|
43
Dominion Energy
D
$59.8B
| $2.1B | 0.66% |
27,375,077
-2,475,551
| -8% | -$195M |
|
|
RAI
44
DELISTED
Reynolds American Inc
RAI
| $1.97B | 0.62% |
30,352,214
-1,186,053
| -4% | -$77.5M |
|
45
McDonald's
MCD
$193B
| $1.85B | 0.58% |
12,058,661
+1,572,074
| +15% | +$227M |
|
46
AT&T
T
$167B
| $1.84B | 0.58% |
64,709,208
-7,253,403
| -10% | -$214M |
|
47
Berkshire Hathaway Class B
BRK.B
$1.11T
| $1.81B | 0.57% |
10,662,527
+501,685
| +5% | +$83.4M |
|
48
Halliburton
HAL
$28.2B
| $1.77B | 0.55% |
41,348,303
-13,451,258
| -25% | -$618M |
|
49
BioMarin Pharmaceuticals
BMRN
$13.4B
| $1.72B | 0.54% |
18,898,699
-744,734
| -4% | -$67.8M |
|
|
K
50
DELISTED
Kellanova
K
| $1.67B | 0.52% |
25,593,790
+9,047,935
| +55% | +$608M |
|
Similar funds
Capital Research Global Investors's Q2 2017 Portfolio in Review
As of Q2 2017, Capital Research Global Investors held 454 positions worth $319B, up 0.77% from $317B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Capital Research Global Investors's Q2 2017 filing shows 29 new, 155 increased, 158 reduced and 23 closed positions. Its largest new stake was L3Harris: 2,791,603 shares worth $305M. The largest sale was Union Pacific, an estimated $1.51B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.
- Capital Research Global Investors's largest Q2 2017 buy was L3Harris: 2,791,603 shares worth $305M.
- Capital Research Global Investors added most to Microsoft in Q2 2017, an estimated $3.25B increase.
- Capital Research Global Investors's biggest Q2 2017 reduction was Union Pacific, cutting an estimated $1.51B.
- Capital Research Global Investors fully exited Mead Johnson Nutrition Company in Q2 2017, selling an estimated $525M.
- Capital Research Global Investors's ten largest holdings make up 24% of its $319B portfolio in Q2 2017.
- Capital Research Global Investors opened 29 new positions and closed 23 in Q2 2017.
- Capital Research Global Investors's portfolio value rose 0.77% quarter-over-quarter to $319B.
Based on Capital Research Global Investors's 13F filing for Q2 2017, filed 14 Aug 2017.